hsa‑microRNA‑411‑5p regulates proliferation, migration and invasion by targeting the hyaluronan mediated motility receptor in ovarian cancer

He,Fang; Zu,Dongyu; Lan,Chong; Niu,Jumin; Nie,Xiaocui

doi:10.3892/etm.2020.8899

hsa‑microRNA‑411‑5p regulates proliferation, migration and invasion by targeting the hyaluronan mediated motility receptor in ovarian cancer

Authors:
- Fang He
- Dongyu Zu
- Chong Lan
- Jumin Niu
- Xiaocui Nie
View Affiliations

Affiliations: Department of Gynecology, Shenyang Women's and Children's Hospital, Shenyang, Liaoning 110011, P.R. China, The Outpatient Department of the First Garrison, General Hospital of The Northern War Zone, Shenyang, Liaoning 110001, P.R. China
Published online on: June 17, 2020 https://doi.org/10.3892/etm.2020.8899
Pages: 1899-1906
Copyright: © He et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The mortality rate of ovarian cancer is the highest out of all gynecological malignancies worldwide. Therefore, it is important to understand the mechanisms of ovarian cancer, identify new biomarkers and develop targeted drugs. The role and molecular mechanisms of hsa‑microRNA (miR)‑411‑5p in ovarian cancer have not been fully elucidated. The present study investigated the ovarian cancer cell lines OVCAR‑8 and SKOV3. After transfection with miRNA mimics, cell proliferation was monitored by a proliferation assay. Furthermore, cell migration was measured by a cell wound healing assay and cell invasion was measured by Matrigel invasion assays. A miRNA luciferase reporter assay was used to analyze the relationship between miRNAs and the target gene HMMR, which was then further evaluated by gene differential analysis. In the current study, hsa‑mir‑411‑5p was identified as a miRNA regulator of the hyaluronan mediated motility receptor, which negatively regulated the activity of ERK1/2 and ultimately inhibited ovarian cancer cell proliferation and motility. Although hsa‑mir‑411‑5p may have different roles in other types of cancer, the present study suggested that miR‑411‑5p functions as a negative tumor regulator in ovarian cancer cells, displaying the potential of miR‑411‑5p as a biomarker for ovarian cancer.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015.PubMed/NCBI View Article : Google Scholar
2	Siegel RL, Miller KD and Jemal A: Cancer Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017.PubMed/NCBI View Article : Google Scholar
3	Suh DH, Kim M, Kim K, Kim HJ, Lee KH and Kim JW: Major clinical research advances in gynecologic cancer in 2016: 10-year special edition. J Gynecol Oncol. 28(e45)2017.PubMed/NCBI View Article : Google Scholar
4	Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R and Jemal A: Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 66:271–289. 2016.PubMed/NCBI View Article : Google Scholar
5	Chornokur G, Amankwah EK, Schildkraut JM and Phelan CM: Global ovarian cancer health disparities. Gynecol Oncol. 129:258–264. 2013.PubMed/NCBI View Article : Google Scholar
6	Croce CM: Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 10:704–714. 2009.PubMed/NCBI View Article : Google Scholar
7	Zaman MS, Maher DM, Khan S, Jaggi M and Chauhan SC: Current status and implications of microRNAs in ovarian cancer diagnosis and therapy. J Ovarian Res. 5(44)2012.PubMed/NCBI View Article : Google Scholar
8	Langhe R: microRNA and ovarian cancer. Adv Exp Med Biol. 889:119–151. 2015.PubMed/NCBI View Article : Google Scholar
9	Xu N, Yang W, Liu Y, Yan F and Yu Z: MicroRNA-411 promoted the osteosarcoma progression by suppressing MTSS1 expression. Environ Sci Pollut Res Int. 25:12064–12071. 2018.PubMed/NCBI View Article : Google Scholar
10	Zhao Z, Qin L and Li S: miR-411 contributes the cell proliferation of lung cancer by targeting FOXO1. Tumour Biol. 37:5551–5560. 2016.PubMed/NCBI View Article : Google Scholar
11	Nadal E, Zhong J, Lin J, Reddy RM, Ramnath N, Orringer MB, Chang AC, Beer DG and Chen G: A MicroRNA cluster at 14q32 drives aggressive lung adenocarcinoma. Clin Cancer Res. 20:3107–3117. 2014.PubMed/NCBI View Article : Google Scholar
12	Xia K, Zhang Y, Cao S, Wu Y, Guo W, Yuan W and Zhang S: miR-411 regulated ITCH expression and promoted cell proliferation in human hepatocellular carcinoma cells. Biomed Pharmacother. 70:158–163. 2015.PubMed/NCBI View Article : Google Scholar
13	Zeljic K, Jovanovic I, Jovanovic J, Magic Z, Stankovic A and Supic G: MicroRNA meta-signature of oral cancer: Evidence from a meta-analysis. Ups J Med Sci. 123:43–49. 2018.PubMed/NCBI View Article : Google Scholar
14	Zhang X, Zhang M, Cheng J, Lv Z, Wang F and Cai Z: MiR-411 functions as a tumor suppressor in renal cell cancer. Int J Biol Markers. 32:e454–e460. 2017.PubMed/NCBI View Article : Google Scholar
15	Shan D, Shang Y and Hu T: MicroRNA-411 inhibits cervical cancer progression by directly targeting STAT3. Oncol Res. 27:349–358. 2018.PubMed/NCBI View Article : Google Scholar
16	Guo L, Yuan J, Xie N, Wu H, Chen W, Song S and Wang X: miRNA-411 acts as a potential tumor suppressor miRNA via the downregulation of specificity protein 1 in breast cancer. Mol Med Rep. 14:2975–2982. 2016.PubMed/NCBI View Article : Google Scholar
17	Zhang Y, Xu G, Liu G, Ye Y, Zhang C, Fan C, Wang H, Cai H, Xiao R, Huang Z and Luo Q: miR-411-5p inhibits proliferation and metastasis of breast cancer cell via targeting GRB2. Biochem Biophys Res Commun. 476:607–613. 2016.PubMed/NCBI View Article : Google Scholar
18	Zhao J, Xu J and Zhang R: MicroRNA-411 inhibits malignant biological behaviours of colorectal cancer cells by directly targeting PIK3R3. Oncol Rep. 39:633–642. 2018.PubMed/NCBI View Article : Google Scholar
19	Deguchi S, Katsushima K, Hatanaka A, Shinjo K, Ohka F, Wakabayashi T, Zong H, Natsume A and Kondo Y: Oncogenic effects of evolutionarily conserved noncoding RNA ECONEXIN on gliomagenesis. Oncogene. 36:4629–4640. 2017.PubMed/NCBI View Article : Google Scholar
20	Sun M, Huang F, Yu D, Zhang Y, Xu H, Zhang L, Li L, Dong L, Guo L and Wang S: Autoregulatory loop between TGF-β1/miR-411-5p/SPRY4 and MAPK pathway in rhabdomyosarcoma modulates proliferation and differentiation. Cell Death Dis. 6(e1859)2015.PubMed/NCBI View Article : Google Scholar
21	Yamamoto K, Seike M, Takeuchi S, Soeno C, Miyanaga A, Noro R, Minegishi Y, Kubota K and Gemma A: MiR-379/411 cluster regulates IL-18 and contributes to drug resistance in malignant pleural mesothelioma. Oncol Rep. 32:2365–2372. 2014.PubMed/NCBI View Article : Google Scholar
22	Kozomara A, Birgaoanu M and Griffiths-Jones S: miRBase: From microRNA sequences to function. Nucleic Acids Res. 47:D155–D162. 2019.PubMed/NCBI View Article : Google Scholar
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
24	Yang JH, Li JH, Shao P, Zhou H, Chen YQ and Qu LH: starBase: A database for exploring microRNA-mRNA interaction maps from Argonaute CLIP-Seq and Degradome-Seq data. Nucleic Acids Res. 39:D202–D209. 2011.PubMed/NCBI View Article : Google Scholar
25	Kim YW, Kim EY, Jeon D, Liu JL, Kim HS, Choi JW and Ahn WS: Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells. Drug Des Devel Ther. 8:293–314. 2014.PubMed/NCBI View Article : Google Scholar
26	Wang SY, Li Y, Jiang YS and Li RZ: Investigation of serum miR-411 as a diagnosis and prognosis biomarker for non-small cell lung cancer. Eur Rev Med Pharmacol Sci. 21:4092–4097. 2017.PubMed/NCBI
27	Zhang C, Wang H, Liu X, Hu Y, Ding L, Zhang X, Sun Q and Li Y: Oncogenic microRNA-411 promotes lung carcinogenesis by directly targeting suppressor genes SPRY4 and TXNIP. Oncogene. 38:1892–1904. 2019.PubMed/NCBI View Article : Google Scholar
28	Ai P, Shen B, Pan H, Chen K, Zheng J and Liu F: MiR-411 suppressed vein wall fibrosis by downregulating MMP-2 via targeting HIF-1α. J Thromb Thrombolysis. 45:264–273. 2018.PubMed/NCBI View Article : Google Scholar
29	Wang G, Zhang Y, Zhao X, Meng C, Ma L and Kong Y: MicroRNA-411 inhibited matrix metalloproteinase 13 expression in human chondrocytes. Am J Transl Res. 7:2000–2006. 2015.PubMed/NCBI
30	Chen H, Mohan P, Jiang J, Nemirovsky O, He D, Fleisch MC, Niederacher D, Pilarski LM, Lim CJ and Maxwell CA: Spatial regulation of Aurora A activity during mitotic spindle assembly requires RHAMM to correctly localize TPX2. Cell Cycle. 13:2248–2261. 2014.PubMed/NCBI View Article : Google Scholar
31	Wang D, Narula N, Azzopardi S, Smith RS, Nasar A, Altorki NK, Mittal V, Somwar R, Stiles BM and Du YN: Expression of the receptor for hyaluronic acid mediated motility (RHAMM) is associated with poor prognosis and metastasis in non-small cell lung carcinoma. Oncotarget. 7:39957–39969. 2016.PubMed/NCBI View Article : Google Scholar
32	Stevens LE, Cheung WKC, Adua SJ, Arnal-Estapé A, Zhao M, Liu Z, Brewer K, Herbst RS and Nguyen DX: Extracellular matrix receptor expression in subtypes of lung adenocarcinoma potentiates outgrowth of micrometastases. Cancer Res. 77:1905–1917. 2017.PubMed/NCBI View Article : Google Scholar
33	Turley EA, Noble PW and Bourguignon LY: Signaling properties of hyaluronan receptors. J Biol Chem. 277:4589–4592. 2002.PubMed/NCBI View Article : Google Scholar
34	Adamia S, Maxwell CA and Pilarski LM: Hyaluronan and hyaluronan synthases: Potential therapeutic targets in cancer. Curr Drug Targets Cardiovasc Haematol Disord. 5:3–14. 2005.PubMed/NCBI View Article : Google Scholar
35	Roskoski R Jr: ERK1/2 MAP kinases: Structure, function, and regulation. Pharmacol Res. 66:105–143. 2012.PubMed/NCBI View Article : Google Scholar
36	Holmström TH, Tran SE, Johnson VL, Ahn NG, Chow SC and Eriksson JE: Inhibition of mitogen-activated kinase signaling sensitizes HeLa cells to Fas receptor-mediated apoptosis. Mol Cell Biol. 19:5991–6002. 1999.PubMed/NCBI View Article : Google Scholar
37	Huang C, Jacobson K and Schaller MD: MAP kinases and cell migration. J Cell Sci. 117:4619–4628. 2004.PubMed/NCBI View Article : Google Scholar
38	Mansour SJ, Resing KA, Candi JM, Hermann AS, Gloor JW, Herskind KR, Wartmann M, Davis RJ and Ahn NG: Mitogen-activated protein (MAP) kinase phosphorylation of MAP kinase kinase: Determination of phosphorylation sites by mass spectrometry and site-directed mutagenesis. J Biochem. 116:304–314. 1994.PubMed/NCBI View Article : Google Scholar
39	Steinmetz R, Wagoner HA, Zeng P, Hammond JR, Hannon TS, Meyers JL and Pescovitz OH: Mechanisms regulating the constitutive activation of the extracellular signal-regulated kinase (ERK) signaling pathway in ovarian cancer and the effect of ribonucleic acid interference for ERK1/2 on cancer cell proliferation. Mol Endocrinol. 18:2570–2582. 2004.PubMed/NCBI View Article : Google Scholar
40	Amsterdam A, Shezen E, Raanan C, Schreiber L, Prus D, Slilat Y, Ben-Arie A and Seger R: Nuclear localization of phosphorylated ERK1 and ERK2 as markers for the progression of ovarian cancer. Int J Oncol. 39:649–656. 2011.PubMed/NCBI View Article : Google Scholar
41	Hatano H, Shigeishi H, Kudo Y, Higashikawa K, Tobiume K, Takata T and Kamata N: Overexpression of receptor for hyaluronan-mediated motility (RHAMM) in MC3T3-E1 cells induces proliferation and differentiation through phosphorylation of ERK1/2. J Bone Miner Metab. 30:293–303. 2012.PubMed/NCBI View Article : Google Scholar
42	Hamilton SR, Fard SF, Paiwand FF, Tolg C, Veiseh M, Wang C, McCarthy JB, Bissell MJ, Koropatnick J and Turley EA: The hyaluronan receptors CD44 and Rhamm (CD168) form complexes with ERK1,2 that sustain high basal motility in breast cancer cells. J Biol Chem. 282:16667–16680. 2007.PubMed/NCBI View Article : Google Scholar